Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I-TACKLE: Pembrolizumab and Cetuximab in Advanced cSCC
NCT03666325Phase 2Unknown
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Oct 2018
- Primary completion
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and cetuximab in cutaneous squamous cell carcinoma (cSCC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Cumulative Overall Response Rate at 15 weeks. Status: unknown.
02
Drugs
pembrolizumabcetuximab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT03666325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03666325.